MIV Therapeutics Inc.

Dr. Dov Shimon is the founder and has been Chief Executive Officer of SagaX Technologies for Medicine, Inc. since 2002. He is a renowned cardiac and thoracic surgeon. In 1977, he graduated with honors from Hadassah Hebrew University Medical School. From 1974-1994, Dr. Shimon trained as a surgeon and cardiothoracic surgeon at Hadassah University Hospital in Israel. From 1984 to 1986, he was the chief resident in cardiovascular surgery at the University of Toronto, Canada. In 1986, he was a heart transplantation fellow at the Medical College of Virginia. He was appointed senior cardiothoracic surgeon at Hadassah in 1987 and was tenured in 1989. He headed Israel's transplant program from 1987 to 1992. In Israel, Dr. Shimon pioneered heart transplantation (1967), lung transplantation (1989), and heart-lung transplantation (1993). He has performed more than 8,000 open-heart operations and thousands of other thoracic operations. Dr. Shimon has more than 17 years of experience in animal and clinical testing of medical devices. He was previously a director of the Artificial Heart Institute in Salt Lake City, UT. He is currently a member of numerous medical and scientific societies, including Mensa International, and has authored many peer-reviewed publications. Dr. Shimon retired as Major from the Israel Defense Forces' Medical Corp. reserves (Paratroopers Battalion), where he had been decorated in 1972. He gained wide experience and has served as a senior military surgeon during the war in Lebanon in 1982-1983 and multiple smaller scale battles. Dr. Shimon completed Senior Business Management studies at Tel Aviv University, School of Management in 1996. He has been working since 1999 with medical device companies in the design and implementation of their preclinical and clinical studies.

Dr. Troczynski jointed MIVT in February 2002 to assist in the development of its proprietary coating technology. His primary area of research is ceramics, in particular bioceramics, and he has focused on the development of biocompatible HAp coatings for metallic substrates, such as medical devices, implants, and stents. Dr. Troczynski is a professor of ceramics at the UBC in the Department of Materials Engineering. He obtained a Ph.D. in materials science and engineering from McMaster University in Hamilton, Ontario in 1987. He has authored many articles in professional journals and has filed a number of patents. Dr. Troczynski is a recognized authority in the field of ceramics and ceramic coatings and is a frequent lecturer at international symposia and scientific forums.

Dr. Chockalingam is a Clinical Professor of Health Care and Epidemiology at UBC. He holds degrees in electronics engineering, biomedical engineering, and medicine. He is an author, educator, lecturer, and internationally recognized cardiovascular expert. Dr. Chockalingam received the Dr. Harold N. Segall award of Merit from the Canadian Cardiovascular Society for outstanding contributions to the progress of cardiovascular disease prevention in Canada. The American College of Cardiology presented him with an honorary fellowship in March 2000. Dr. Chockalingam has authored or co-authored over 100 scientific/medical publications.

Dr. Savard has more than 20 years of clinical practice and research experience as a cardiologist. He is a professor of medicine at the University of Montreal. Dr. Savard has participated in more than 40 clinical trials and international multicenter studies and has published dozens of manuscripts. His research areas include coronary heart disease, congestive heart failure, arterial hypertension, and angiogenesis therapy in congestive heart failure. He has been a member of several large pharmaceutical clinical advisory boards including Pfizer Inc. (PFE-NYSE), Aventis SA (AVE-NYSE), Biovail Corp. (BVF-NYSE), and Crystaal Corporation. He currently consults for Biovail and Medisys PLC (MDIYF.PK).

Dr. Greg L. Kaluza, M.D., Ph.D, F.A.C.C. is a recognized expert in the field of interventional cardiology. He has been published well over sixty times, including many engagements as a world recognized public speaker at major scientific symposiums. His main research interests are prevention of restenosis, local drug delivery, development of bioresorbable stents, biocompatibility testing of medical device coatings, utility of intravascular ultrasound in predicting histologic outcomes in animal models of restenosis and atherosclerosis, as well as evaluation of Optical Coherence Tomography as a tool to monitor arterial responses to stenting, particularly bioresorbable stents. Dr. Kaluza is Scientific Director of the Center for Research in Cardiovascular Interventions (CRCI) at the Methodist Hospital Research Institute in Houston, Texas. The CRCI is a multifaceted, highly specialized group focused on research in interventional cardiology. The CRCI includes an experimental animal laboratory, a cardiovascular angiographic analysis core, and a clinical research department. Dr. Kaluza advises the company's on clinical trials and other key research programs.